WHO and Switzerland cement cooperation until 2028

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-17T08:21:32.243Z • Permanent link

Renewed cooperation between the World Health Organization (WHO) and Switzerland has been announced, with the two entities agreeing to a new cooperation strategy that will span the period 2024-2028. The agreement marks a significant development in the global health landscape, building on the successful partnership that has been in place since 2013. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, welcomed the renewal of the cooperation, highlighting the importance of Switzerland's commitment to global health.

Switzerland's pioneering role in WHO cooperation dates back to 2013, when it became the first high-income country in the WHO European Region to pilot a cooperation strategy with the organization. Since then, the partnership has yielded tangible results, including the development of innovative solutions to address pressing global health challenges. The renewed agreement will see continued collaboration on a range of initiatives, including healthcare systems strengthening, research, and emergency preparedness.

Key stakeholders, including the Swiss Federal Department of Foreign Affairs and the WHO European Region, have welcomed the renewal of the cooperation. Dr. Hanspeter Moser, Director-General of the Swiss Federal Department of Foreign Affairs, praised the partnership, stating that it was a "crucial element" in addressing global health challenges. The renewed agreement is expected to be finalized in the coming months, with implementation set to begin in 2024.

The renewed cooperation between WHO and Switzerland has significant implications for the global health landscape, particularly in the context of the COVID-19 pandemic. The agreement is likely to have a direct impact on the development of healthcare systems, research initiatives, and emergency preparedness measures. Companies involved in healthcare technology, pharmaceuticals, and medical device manufacturing will also benefit from the renewed partnership, as it is expected to drive innovation and collaboration in these sectors.

Research communities, policymakers, and markets will also be affected by the renewed cooperation. The WHO European Region is home to several major research institutions, including the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA). The renewed partnership is expected to enhance collaboration between these institutions and their counterparts in Switzerland, driving the development of new treatments, vaccines, and diagnostic tools. Furthermore, the agreement is likely to influence policy decisions at the European and national levels, shaping the development of healthcare systems and regulatory frameworks.

The renewed cooperation between WHO and Switzerland is part of a broader pattern of international collaboration in global health. In recent years, there has been a growing recognition of the need for collective action to address global health challenges, driven in part by the COVID-19 pandemic. The WHO European Region has been at the forefront of this effort, with several countries, including Switzerland, playing a key role in the development of regional responses to the pandemic.